Clinical Trials
16
Active:2
Completed:12
Trial Phases
3 Phases
Phase 1:9
Phase 2:2
Phase 3:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Phase 1
9 (56.3%)Phase 3
5 (31.3%)Phase 2
2 (12.5%)Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years
Phase 1
Active, not recruiting
- Conditions
- Varicella Zoster Virus InfectionHerpes Zoster
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- EuBiologics Co.,Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT06409494
- Locations
- 🇰🇷
The Catholic University of Eunpyeong St.Mary's Hospital, Seoul, Korea, Republic of
Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years
Phase 1
Active, not recruiting
- Conditions
- Respiratory Syncytial Virus (RSV)Respiratory Syncytial Virus Infections
- Interventions
- Other: Placebo Comparator
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- EuBiologics Co.,Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT06216093
- Locations
- 🇰🇷
Univsersity Hospital, Seoul, Korea, Republic of
Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old
Phase 1
Completed
- Conditions
- Infection, Meningococcal
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- EuBiologics Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT05739292
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- EuBiologics Co.,Ltd
- Target Recruit Count
- 2852
- Registration Number
- NCT05603052
- Locations
- 🇨🇩
Trial site, Kinshasa, Congo, The Democratic Republic of the
A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults
Phase 3
Completed
- Conditions
- COVID-19
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- EuBiologics Co.,Ltd
- Target Recruit Count
- 2600
- Registration Number
- NCT05572879
- Locations
- 🇵ðŸ‡
Trial site, Manila, Philippines
- Prev
- 1
- 2
- 3
- Next
News
No news found